Review

The Influence of Pharmacogenetics on the Clinical Relevance of Pharmacokinetic Drug–Drug Interactions: Drug–Gene, Drug–Gene–Gene and Drug–Drug–Gene Interactions

Martina Hahn 1,2,* and Sibylle C. Roll 3

1 Klinik für Psychiatrie, Psychosomatik und Psychotherapie des Universitätsklinikums Frankfurt, 60528 Frankfurt, Germany
2 Dr. Amelung Privatklinik, 61462 Königstein, Germany
3 Klinik für Psychische Gesundheit, Klinikum Frankfurt Höchst, 65929 Frankfurt, Germany; Sibylle.Roll@KlinikumFrankfurt.de
* Correspondence: martina.hahn@kgu.de

Abstract: Drug interactions are a well-known cause of adverse drug events, and drug interaction databases can help the clinician to recognize and avoid such interactions and their adverse events. However, not every interaction leads to an adverse drug event. This is because the clinical relevance of drug–drug interactions also depends on the genetic profile of the patient. If inhibitors or inducers of drug metabolising enzymes (e.g., CYP and UGT) are added to the drug therapy, phenocconversion can occur. This leads to a genetic phenotype that mismatches the observable phenotype. Drug–drug–gene and drug–gene–gene interactions influence the toxicity and/or ineffectivness of the drug therapy. To date, there have been limited published studies on the impact of genetic variations on drug–drug interactions. This review discusses the current evidence of drug–drug–gene interactions, as well as drug–gene–gene interactions. Phenoconversion is explained, the and methods to calculate the phenotypes are described. Clinical recommendations are given regarding the integration of the PGx results in the assessment of the relevance of drug interactions in the future.

Keywords: drug–drug interactions; drug–gene interactions; drug–g–gene interactions; phenoconversion; pharmacogenetics

1. Intoduction

Drug–Drug-Interactions (DDI) are a well-known cause of adverse drug events [1–3]. The number of potential drug interactions increases exponentially with the number of taken drugs, making it hard to consider all drug interactions in polypharmacy patients. Drug interaction databases can help the clinician to recognize and avoid adverse drug interactions [4]. A phenomenon can be observed in daily practice, though: even if a database warns about a clinically relevant DDI, the patient may not show any signs of a given DDI. This discrepancy between scientific evidence and clinical reality causes alert fatigue and also raises conflicts between the DDI warning pharmacists and no adverse drug event-observing physicians [5].

Pgx testing has become more popular over the last decade, but it is not yet a routine test, except in oncology. However, there is growing evidence that large proportions of patients are affected by an actionable genotype—a genotypes where a change in prescribing may be indicated. The evidence for Drug–Gene-Interactions (DGI) exists for many drug–gene pairs already. In pediatric patients, for example, the annual prescribing prevalence of at least one level A drug (recommendations for drugs available with high evidence regarding a particular genotype) ranges from 7987 to 10,629 per 100,000 patients [6]. Turner analyzed the data from non-ST elevation myocardial infarction patients (n = 1456) and found that 98.7% of the patients had at least one actionable genotype [7]. Within the
interaction cohort (drug use and actionable genotypes available), 882 interactions were identified in 503 patients (77.1%), of which 346 interactions in 252 patients (38.7%) were substantial: 59.2%, 11.6%, 26.3%, and 2.9% substantial interactions were DDIs, DGIs, Drug–Drug–Gene-Interactions (DDGIs) and Drug–Gene–Gene-Interactions (DGGIs), respectively (see Table 1 for definitions). This shows that preemptive PGx testing could lead to a reduction in the clinically relevant interactions, especially in patients with polypharmacy.

| Term                              | Definition                                                                                                                                 |
|-----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| Drug–Drug Interaction             | When a drug in the individual’s regimen affects that individual’s ability to clear another drug.                                             |
| Drug–Gene Interaction             | When an individual’s genetic phenotype affects that patient’s ability to clear a drug.                                                      |
| Drug–Drug–Gene Interaction        | When the individual’s genetic AND another drug in the individual’s regimen affects that individual’s ability to clear a drug.               |
| Phenocconversion                  | Mismatch between the individual’s genotype-based prediction of drug metabolism and true capacity to metabolize drugs due to non-genetic factos (e.g., inflammation, pregnancy, liver failure, GFR, smoking, gender, and comedication). |
| Drug–Gene–Gene Interaction        | Mismatch between the expected capacity to metabolize a drug that is caused by a second metabolizing (alternative pathway) enzyme’s genotype. |
| Victim Drug                       | Substrate of drug-metabolizing enzymes that are induced or inhibited in combination with a perpetrator drug (inhibitor or inducer). The serum levels of the victim drug changes by this Drug–Drug-Interaction. |
| Perpetrator Drug                  | Inhibitor or inducer of drug-metabolizing enzymes that increases or decreases the serum levels of the victim drug. The serum level of the perpetrator drug does not change. |

There are several organizations, such as the Dutch Pharmacogenetics Working Group (DPWG), the Clinical Pharmacogenetics Implementation Consortium (CPIC), the Canadian Pharmacogenomics Network for Drug Safety (CPNDS), and the French National Network (Réseau) of Pharmacogenetics (RNPGx), that have developed clinical guidelines to help the clinician translating the scientific findings into clinical treatment recommendations. As we understand more about DDGIs and DGGIs, the influence of genetic variants on the drug level is becoming clearer and better understood. A problem in prior studies was that clinical genotype-focused association studies did not take pharmacokinetic DDIs into consideration. Typically, those studies focused on the drug metabolizing enzyme (DME) genotypes of the study population and assumed that genotypes of all the study subjects predict their functional phenotype. Despite wide inter- and intra-genotype variability in the metabolic capacity, clinical responses are thought to be simple binary outcomes for genotype groups. The aim of these studies was to examine the strength of the associations between genotype and clinical phenotype and, if shown to be strong, to develop a dosing regimen appropriate to each genotype. By not taking DDIs, DDGIs, and DGGIs into consideration, they may have missed clinically strong pharmacogenetic associations, thus compromising any potential for advancing the prospects of personalized medicine. Many studies, however, were not able to find those strong associations, which lead to the argument that PGx is not valuable in clinical practice.

Currently, most guidelines on DDIs neither consider the potential effect of genetic polymorphisms in the strength of the interaction nor do they account for the complex interaction caused by the combination of DDI and DGI when there are multiple biotransfor-
mation pathways, referred to as DGGI. Not surprisingly those guidelines often contradict each other [8]. Therefore, all the studies with only PGx results, as well as studies in which only DDIs were reported, are probably incorrect and will, thus, lead to false conclusions and potentially damaging clinical recommendations. Therapeutic drug monitoring (TDM)—a gold standard to monitor pharmacokinetic DDIs—is very helpful but cannot avoid adverse drug reactions in the beginning of a drug therapy, because TDM can only be carried out after five half-lives of the drug when a steady state is reached.

Taken together, this has led many clinicians to the conclusion that PGx testing is not reliable. There is an uncertainty about when and whom to test, and few guidelines actually give a clinical recommendation in relation to this. It is important to understand the route of the drug through the body (LADME principle) and then understand how a SNP influences the absorption, distribution, metabolism, and excretion of the drug. We need “the whole picture” of the patient with all the comedication to predict the efficacy and tolerability of a drug.

In this review, we provide a framework for the classification of pharmacokinetic DDGIs and DGGI caused by different mechanisms, and their potential impact on drug serum levels in the context of polypharmacy.

2. Pharmacokinetic Drug–Drug Interactions

In the past, the magnitude and clinical importance of drug interactions was often neglected [9] because of overalerting DDIs in clinical practice [10–12]. The CYP-inhibitory or -inducing potential of a drug and the substrate specificity of the potential victim drug must be considered (Table 2). CYP perpetrator drugs are inhibitors or inducers of CYP enzymes. CYP perpetrator drugs affect the metabolism of victim drugs (CYP substrates) and lead to an increase or decrease in serum concentrations of the victim drugs. The Food and Drug Administration categorizes CYP inhibitors or inducers as strong, moderate, or weak based on pharmacokinetic DDI studies [13]. CYP inhibitors that were categorized as “strong” (> fivefold increase in area under the plasma concentration–time curve (AUC) or > 80% decrease in clearance) or “moderate” (> twofold but < fivefold increase in the AUC or 50–80% decrease in clearance) and CYP inducers categorized as “strong” (≥ 80% decrease in AUC) or “moderate” (50–80% decrease in AUC) can be regarded as clinically relevant. Several tables of drugs as substrates, inhibitors, and inducers of drug-metabolizing CYP enzymes have been published in the past [14,15]. The categorization into strong, moderate, and weak allows a first grading into “relevant” or irrelevant “pharmacokinetic DDIs. However, in clinical practice, this classification is not always correct, and it may be related to genetic polymorphisms and DDIs, DDGs, and DGGS, as described in the next sections.

| CYP | Known Phenotypes | Substrates | Phenoconversion |
|-----|------------------|------------|----------------|
| 1A2 | increased function | duloxetine, olanzapin, clozapine, theophyllin, caffeine | fluvoxamine, ciprofloxacin, enoxacine, smoking |
|  | normal function |unknown function |            |
| 2A6 | PM, IM, NM, UM | nicotine |                |
| 2B6 | NM, IM, PM, RM, UM | bupropion, cyclophosphamide, efavirenz, methadone | clopidogrel, ticlopidine, tenofovir, voriconazole, carbamazepine, efavirenz, rifampin |
| 2C8 | increased function | glitazones, paclitaxel | gemfibrozil, clopidogrel, teriflunomide, trimethoprim, rifampin, St. John’s wort |
| | normal function | decreased function |            |

Table 2. CYP enzymes, their phenotypes, substrates, and drugs that can cause phenoconversion by inhibition or induction. Underlined: CYP inducers. NM = normal metabolizers; IM = intermediate metabolizers; PM = poor metabolizers; RM = rapid metabolizers; UM = ultra-rapid metabolizers; NSAIDs = nonsteroidal antiinflammatory drugs. Examples from http://go.drugbank.com, accessed on 29 March 2021.
Table 2. Cont.

| CYP | Known Phenotypes                  | Substrates                                                                 | Phenocconversion                          |
|-----|-----------------------------------|-----------------------------------------------------------------------------|-------------------------------------------|
| 2C9 | NM, IM, PM                       | losartan, NSAIDs, phenytoin, warfarin, glyburide                            | amiodarone, fluconazole, miconazole, rifampin |
| 2C19| NM, IM, PM, RM, UM               | clopidogrel, diazepam, proton pump inhibitors (PPI)                         | fluvoxamine, fluoxetine, fluconazole, omeprazole, ticlopidine, rifampin |
| 2D6 | NM, IM, PM, UM                   | antidepressants, betablockers, codeine, tramadol, tamoxifen, hydrocodone    | bupropion, cimetidine, duloxetine, fluvoxamine, fluoxetine, paroxetine, quinidine, Note: there are no known inducers of CYP2D6. |
| 3A4 | normal function, decreased function, increased function | calcium channel blockers, macrolides, protease inhibitors, statins | azole antymycotics, boceprevir, cobicistat, danoprevir, grapefruit, ritonavir, telaprevir, verapamil, carbamazepine, phenobarbital, phenytoin, rifampin, SE. John's wort |
| 3A5 | NM, IM, PM                       | Note: activity has major influence on CYP3A4 activity, if *1 is present     | Tacrolimus, quetiapine                    |

3. Drug–Gene Interactions

A genetic polymorphism is a variation in DNA sequence that leads to a reduced or increased activity of a DME. There are several different types of polymorphisms that can affect DGIs:

Single-Nucleotide Polymorphisms (SNPs), with a change of a single base pair, insertions or deletions, a variable number of tandem repeats (VNTR), and copy number variants (CNV), where the number of copies varies between individuals [16]. SNPs can cause:

(a) a change in the codon, which might change the amino acid that is transcribed;
(b) a premature stop codon (no functional protein is formed);
(c) different intron and exon splice junctions (no functional protein is formed);
(d) an alteration in the stability of the mRNA (no proteins are formed);
(e) a change in enhancer activity (gain of function);
(f) or even no discernible consequence.

It is important to emphasise that SNPs—the change of a single base—can lead to a “loss of function”, “a decrease in function”, “a gain of function”, or even to no formation of DME at all, to understand phenocconversion in the later sections. From the definition, one can distinguish a haplotype (one allele, e.g., *1) from a diplotype (two alleles, e.g., *1/*41). Now, a genotype is the DNA sequence of an organism at a specific, defined location. In PGx, the term is used to describe a certain gene, e.g., CYP2D6 (Figure 1). The genotype could be an IM/PM (intermediate metabolizer/poor metabolizer). A phenotype, in comparison, is the observable trait (e.g., blue eyes) or enzyme activity score of the DME in a patient. The genetic phenotype of DME can be divided into a poor, normal, intermediate, rapid, and ultra-rapid metabolizer status, taking both genotypes into consideration, e.g., IM/PM genotypes equals the IM phenotype; NM/IM genotype equals the NM phenotype. This takes both inherited genotypes into account (Figure 1). The phenotype can be observed by using TDM.

Many studies have shown that the efficacy and risk of side effects of a drug treatment is influenced by genetic variants of the DMEs and the transporters. Evidence-based guidelines with pharmacotherapeutic recommendations for combinations of specific drugs and genotypes or predicted phenotypes are essential for implementing acquired pharmacogenetic knowledge in daily clinical practice. The DPWG CPIC, CPNDS, and RNPGx have developed guidelines according to the genetic phenotypes of the patient. They also
published a study to standardize the genotype-to-phenotype translation [17]. The impact of 440 genetic variants on the pharmacokinetics and pharmacodynamics of drugs are available at the CPIC website: www.cpicpgx.org, accessed on 29 March 2021.

Figure 1. Explanation how to transfer a SNP to an activity score (first line) and how to calculate the phenotype from the diplotype (second line).

4. Genetic Polymorphisms of DME of Phase I Metabolism

Several genes encoding cytochrome P450 enzymes are highly polymorphic, especially CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A5. This requires a translation of genotypes into predicted genetic phenotypes. For DMEs, we know four different activities levels of the enzymes: normal function, decreased function, loss of function, and increased function.

This results in five different genetic phenotypes: normal metabolizer (NM), intermediate metabolizer (IM), poor metabolizer (PM), rapid metabolizer (RM), and ultra-rapid metabolizer (UM).

Studies have shown that DGIs change the efficacy and adverse drug event rate. Over the last decades, especially in relation to drugs with a narrow therapeutic index or prognosis, changing drugs like warfarin (CYP2C9 genotype and risk of hemorrhage or stroke), tamoxifen (CYP2D6 genotype and risk of therapeutic failure), clopidogrel (CYP2C19 genotype and risk of thrombotic cardiovascular outcomes), irinotecan (UGT1A1 genotype and risk of myelosuppression), and thiopurines (TPMT genotype and/or phenotype and risk of myelosuppression) were a focus of research. FDA label changes were conducted, and preemptive genotyping was recommended before starting drugs with a high toxicity and, therefore, a high risk for the patient to suffer from a severe adverse drug reaction. DPWG gives specific clinical recommendations for 54 DGIs already (see http://upgx.eu/guidelines, accessed on 29 March 2021).

Of all the DMEs, CYP2D6 and CYP2C19 are the most polymorphic. If there is a decreased activity (intermediate and poor metabolizers), a higher drug concentration increases the risk for adverse drug events and toxicity. If there is an increased activity (rapid and ultra-rapid metabolizers), a lower drug concentration is reached, and this results in a risk for therapeutic failure. These enzymes play a prominent role in the drug metabolism of psychotropic drugs, e.g., antidepressants, antipsychotics, and nonstimulants like atomoxetine but, also, opioids, betablockers, and proton-pump inhibitors. Adverse events, response failures, and/or medication nonadherence are common in patients receiving
medications for the treatment of mental illness. This might be caused by DGIs in these patients. In psychopharmacotherapy, the CPIC and DPWG have developed guidelines and give treatment recommendations for SSRIs, TZAs, atomoxetine, and opioids, among others, in regards to the patient phenotypes of CYP2C19 and/or CYP2D6.

For CYP enzymes, there is a genotype activity score definition (Table 3). Depending on the two scores of each allele, the phenotype can be calculated, e.g., *4/*1 equals an activity score of 0 + 1 = 1. The patient’s genetic phenotype would be intermediate metabolizer (Figure 1).

| Activity Score | Alleles (Examples) | Type of Allele and Genotype          |
|----------------|--------------------|--------------------------------------|
| >2.25          | *1/*1 N, *1/*2 N, *2/*2 N, *1 /*2/*9 | Increased activity, Ultra rapid metabolizer |
| ≤2.25 to >1.25 | *1/*10, *1/*41, *1/*9, *1/*1, *1/*2, *2 /*2/*10 | Wild-type, Normal metabolizer          |
| >0 to <1.25    | *4/*10, *4/*41, *10/*10, *10/*41, *41/*41, *1/*5 | Reduced function, Intermediate metabolizer |
| 0              | *3/*4, *4/*4, *5/*5, *5/*6 | Non-functional, Poor metabolizer       |

Pharmacokinetic Drug–Gene-Interactions influence the serum concentration of the drug. Chang et al., for example, showed that there was an increase in the escitalopram levels of 95% and 30% in the poor and intermediate metabolizers of CYP2C19 compared to normal metabolizers, respectively. Rapid and ultra-rapid metabolizers were demonstrated to have a decrease in the escitalopram levels of 13% and 36%, respectively [18]. This is an important finding, because only 13% of psychiatric inpatients with a major depressive disorder are normal metabolizers of both CYP2C19 and CYP2D6 [19]. Hicks et al. provided specific recommendations in the CPIC guidelines on the dosing and use of SSRIs and tricyclics for each phenotype [20].

Clopidogrel, an antiplatelet agent that reduces the risk of myocardial infarction (MI) and stroke in patients with acute coronary syndrome (ACS), and in patients with atherosclerotic vascular disease, is another common example for DGIs. Clopidogrel is also indicated in combination with aspirin in patients undergoing percutaneous coronary interventions (PCI), e.g., the placement of a stent. The effectiveness of clopidogrel depends on its conversion to an active metabolite by CYP2C19. Individuals who carry two nonfunctional copies of the CYP2C19 gene are classified as CYP2C19-poor metabolizers. They have no enzyme activity and cannot activate clopidogrel via the CYP2C19 pathway, which means the drug will have no effect. Approximately 2% of Caucasians, 4% of African Americans, and 14% of Chinese are CYP2C19-poor metabolizers. Given the strong evidence for this DGI, the 2017 FDA-approved drug label for clopidogrel includes a boxed warning concerning the diminished antiplatelet effect of clopidogrel in CYP2C19-poor metabolizers. The warning states that tests are available to identify patients who are CYP2C19-poor metabolizers and to consider the use of another platelet P2Y12 inhibitor in patients identified as CYP2C19-poor metabolizers. CYP2C19-poor and -intermediate metabolizers also have an increased risk for ischemic stroke, myocardial infarction, and coronary angioplasty [21].

DGIs also play an important role in oncology therapies/treatment. Adjuvant tamoxifen therapy reduces breast cancer mortality by 31%. However, the tamoxifen effectiveness varies widely between individuals. Tamoxifen is a drug that requires metabolic activation by CYP2D6 to elicit its full pharmacologic activity, because the corresponding metabolites 4-OH-tamoxifen and endoxifen exhibit much higher binding affinities to the estrogen receptor than the parent compound. A study by He et al. showed that both poor and ultra-
rapid metabolizers have a worse prognosis and a higher mortality compared to normal metabolizers when given tamoxifen. Poor metabolizers have a decreased efficacy, because the 4-OH-tamoxifen and endoxifen are not formed. Ultra-rapid metabolizers have more adverse drug events and a higher risk for discontinuation of tamoxifen and, in consequence, a worse prognosis [22].

For phase 1 enzymes, more adverse drug reactions in CYP2D6 ultra-rapid metabolizers are also documented for codeine (respiratory failure). Thus, especially for prodrugs, a fast metabolism to the active metabolite can cause toxicity. Examples of the substrates, inhibitors, and known genotypes are listed in Table 2.

5. DMEs of Phase 2 Metabolism

Some drugs undergo a metabolism in phase 2. In addition, there are several genetic polymorphisms known for these DMEs. There are a few examples that exist, revealing that the metabolites are more toxic than the parent drug, e.g., estradiol-17 glucuronide causes more adverse drug events than estradiol itself. Usually, the inhibition of phase 2 DMEs results in an increase in the serum levels and, therefore, a higher toxicity. Examples of substrates, inhibitors and inducers can be found in Table 4.

Table 4. Examples for phase 2 DME, phenotypes, substrates and inhibitors/inducers. N.a. = not applicable; NM = normal metabolizers; IM = intermediate metabolizers; PM = poor metabolizers; RM = rapid metabolizers; UM = ultra-rapid metabolizers. Examples are from the pharmgkb database: www.pharmgkb.org, accessed on 29 March 2021.

| Enzyme | Known Phenotypes | Substrates | Phenoconversion |
|--------|------------------|------------|----------------|
| UGT1A1 | NM, IM, PM       | bilirubin, irinotecan, estradiol | Atazanavir, carbamazepine, phenytoin, phenobarbital, rifampicin, ritonavir, lamotrigine, efavirenz, tyrosine-kinase inhibitors |
| UGT1A4 | Normal function, increased function, decreased function | valproic acid, lamotrigine, allopurinol, febuxostat, tamoxifen, clozapine, anastrozole | methylene blue, ertugliflozin, carbamazepine, phenytoin |
| UGT1A6 | n.a. | allopurinol, febuxostat, methotrexat, valproic acid | troglitazone, fosphenytoin, phenytoin, carbamazepine |
| UGT1A9 | n.a. | allopurinol, febuxostat, methotrexat, valproic acid | vandetanib |
| UGT2B7 | n.a. | zodovudine, oxycodone, efavirenz, methadone, lamotrigine, morphine, codeine, fentanyl | flunitrazepam, ketoconazole, umifenovir, phenobarbital, mefenamic acid |
| UGT2B15 | normal function, decreased function | oxazepam, lorazepam |
| NAT2   | fast slow | isoniazid, hydralazine, dapsone, caffeine, procainamide |
| TPMT   | NM, IM, possibly intermediate, PM | thiopurines | allopurinol |
| NUDT15 | NM, IM, possibly intermediate, PM | thiopurines |

6. Drug Transporters (Phase 3)

Even at “normal” serum levels, drugs can show no efficacy, because they are unable to cross certain barriers in the body (e.g., the blood–brain barrier), or they can be highly toxic if they accumulate intracellularly (e.g., tenofovir-induced tubular toxicity in patients
with an ABCC2 polymorphism). By only measuring the serum concentration (TDM), those changes in the pharmacokinetics of the drug cannot be identified (and not be avoided). Hence, PGx testing can help to avoid ADRs and increase the efficacy, ideally in combination with TDM.

There are two major transporter superfamilies: the ABC transporter and the SLC transporter, consisting of the ABC transporter and SLC transporter families (e.g., ABCC family or SLC21 family) (Table 5). They play an important role in the absorption (intestine), distribution (blood–brain barrier, placenta, and testes), metabolism (liver), and excretion (biliary and renal) processes. Genetic variants of the transporters modulate the absorption, distribution, metabolism, and excretion of the drugs. A prominent example is statin-induced myopathy in carriers of the OATP1B1*5 polymorphism. Furthermore, bile salt export pump polymorphisms are known to cause drug-induced liver injury (DILI), which accounts for 20–40% of all hepatic failure cases observed worldwide [23]. A polymorphism of the multidrug-resistant protein type 2 (MRP2) increases the kidney toxicity of tenofovir administration [24].

### Table 5. Examples for influx and efflux transporters, their genotypes, and examples of the substrates and interacting drugs causing phenoconversion. Underlined drugs: inducers for the transporter. Examples were retrieved from the pharmgkb database: www.pharmgkb.org, accessed on 29 March 2021.

| Gene/Transporter | Known Phenotypes               | Substrates                                                                 | Phenoconversion               |
|------------------|--------------------------------|---------------------------------------------------------------------------|-------------------------------|
| OATP1B1/SLCO1B1  | normal function, decreased function, poor function | atorvastatin, repaglinide, enalapril, methotrexate, rosuvastatin, simvastatin, erythromycin, nateglinide, pitavastatin, pravastatin, lopinavir | astemizole, diazepam, nifedipine |
| BCRP/ABCG2       | Normal function, decreased function | allopurinol, asuvastatin, lefunomide, sunitinib, topotecan, pitavastatin, rosuvastatin, sulfasalazine | curcumine, elacridar, cyclosporine A |
| P-glycoprotein/ABCB1/MDR1 | normal function, increased function | colchicine, fexofenadine, simvastatin, rifampin, cyclosporine, ondansetron, risperidone, digoxin, fentanyl, methadone, oxycodone, tramadol, phenytoin | amiodarone, carvedilol, clarithromycin, quinidine, verapamil, ritonavir, telaprevir, carbamazepine, St. John’s wort, primidone, rifampin, phenytoin |

Additionally, in epileptic patients, a transporter was found to be responsible for drug therapy resistance. About 30% of epileptic patients do not respond to P-gp substrates but do if a P-gp inhibitor is added to drug therapy [25,26], an example of how relevant phenoconversion can be in clinical practice if employed on purpose. The same effect is proposed for antidepressants and mood stabilizers [27–29].

It has been estimated that half of the patients above 65 years will use at least one drug for which PGx guidelines are available during a four-year period, and 25–33% will use two or more of these drugs [30].

### 7. Drug–Gene–Gene Interactions (DGGIs)

DGGIs can explain why, even if we consider all known DGIs and DDIs, there are serum levels that we cannot explain by those two factors alone. If two or more CYP enzymes metabolize a drug, then inhibition of one of these enzymes alone (by drug or genotype) may have minimal effect, due to redundancy of the pathways (Figure 2).
Figure 2. (1) Normal metabolism in normal metabolizers results in metabolism to metabolite A. (2) Drug–Drug-Interactions, e.g., a combination with an inhibitor of the drug-metabolizing enzyme, results in a decreased metabolism of the drug into metabolite A. The serum levels of drug A is increased compared to normal metabolism. (3) DGI: the phenotype of the drug-metabolizing enzyme determines the metabolism rate into an (active) metabolite, e.g., the phenotype IM leads to a decreased metabolism of the drug. A high drug concentration of the parent drug can be found by using TDM. (4) DDGI: an inhibitor or inducer of a drug-metabolizing enzyme changes the phenotype by phenoconversion. This changes the serum levels of the drug, e.g., increases the serum levels of the drug and decreases the levels of the metabolite A, e.g., if both the phenotype and perpetrator drug limit the drug metabolism, high serum levels of the parent drug can be found. (5) DGGI: the phenotype of two drug-metabolizing enzymes determines the formation of metabolite A and B, e.g., if the main pathway is “closed” due to a poor or intermediate metabolizer status, the phenotype of the drug-metabolizing enzyme of the second pathway determines the speed of the metabolism. Metabolite B is formed to a larger extent than metabolite A.

If a patient is an intermediate metabolizer for CYP2D6 and CYP2C19, a dose reduction might be indicated, while it is not recommended in CYP2D6 NM and CYP2C19 IM. Thus, the genotype of the second enzyme also influences the overall metabolism and, in consequence, the serum level. For tricyclic antidepressants, the CPIC guideline gives specific recommendation in a cross-table for each CYP2D6 and CYP2C19 genotype combination [20]. The same guidelines exist for thiopurines with the TMPT and NUDT15 genotypes [31] and statins with the SLC01B1 and ABCG2 genotypes [32]. This underlines how important the testing of a panel rather than a single DME genotype is.  Bousman et al. recommended a testing panel for psychiatry that covers most of the DMEs. DPWG recommends a PGx passport that encompasses 58 variant alleles within 14 pharmacogenes (CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A5, DPYD, F5, HLA-B, NUDT15, SLC01B1, TMPT, UGT1A1, and VKORC1) and can be used to optimize the pharmacotherapy for 49 commonly prescribed drugs throughout a patient’s lifetime [33].

In drugs that utilize more than two pathways, predicting the drug serum level becomes even more complicated. This complexity shows the importance of PGx-specialized clinical
Pharmacists to help interpret the results, taking drug interactions, as well as lifestyle factors, into account when giving recommendations. CPIC guidelines recommend the consultation of a clinical pharmacist if actionable genotypes are discovered. Many universities now offer PGx training and specializations for pharmacists.

How do genetic polymorphisms and drug interactions influence each other?

8. Drug–Drug–Gene Interactions (DDGIs) and Phenoconversion

Phenoconversion is the conversion of a genetic phenotype (i.e., PM, IM, NM, and UM) into a different phenotype by comedication or other nongenetic factors and is quite common [32]. Phenoconversion is a complex phenomenon that leads to genotype–phenotype mismatching without any genetic abnormality. It is particularly well-characterized for cytochromes P450 2D6 and 2C19. Although transient, phenoconversion can have a significant impact on the analysis and interpretation of genotype-focused clinical outcome correlations and in forensic toxicology conclusions [34] but, also, in everyday clinical practice. Phenoconversion resulting from nongenetic extrinsic factors has a significant impact on the analysis and interpretation of genotype-focused clinical outcome association studies and, ultimately, to the personalization of therapy in routine clinical practice. Having the genotype data available can help identify those nongenetic factors, which may lead to a decreased risk for the patient to suffer from adverse drug reactions by following a different treatment algorithm (e.g., order TDM, treat the infection, avoid the drug interaction, etc). Examples of nongenetic factors include inflammation, cancer, age, liver disease, and renal dysfunction [35].

The high phenotypic variability or genotype–phenotype mismatch, frequently observed due to phenoconversion within the genotypic NM population, means that the real number of phenotypic PM subjects is likely to be greater than predicted from their genotype alone. This is because many genotypic NMs would be phenotypically PMs [36]. Mostafa et al. analyzed an Australian cohort and found an increase in actionable genotypes due to phenoconversion in a large proportion of patients. The number of CYP2D6 PM increased from 5.4% (genotype predicted) to 24.7% (adjusted phenotype) by phenoconversion [33]. For the CYP2C19 PM phenotype, the rate increased from 2.7% (genetic phenotype) to 17% (adjusted phenotype) by taking phenoconversion due to DGIs into account.

In Drug–Drug–Gene-Interactions, the drug interaction becomes clinically relevant due to the genetic polymorphism. For example, if a CYP2D6 NM patient on metoprolol 50 mg per day receives a strong inhibitor for CYP2D6, the serum levels of metoprolol will probably increase fivefold. However, if the patient is a CYP2D6 PM, the levels of metoprolol will not change at all if a strong inhibitor for CYP2D6 is coprescribed. Citalopram is another prime example of a DDGI, as it is metabolized by both CYP2D6 and CYP2C19. In detail, if a patient is IM for CYP2D6 and NM for CYP2C19, they can receive a “normal” drug dose, because the main metabolic pathway is “open” (NM status). Now, if said patient receives a CYP2C19 inhibitor, such as omeprazole, the drug level will increase significantly due to the inhibition of the CYP2C19 and IM status on CYP2D6. Finally, if the patient is UM for CYP2D6 and receives the CYP2C19 inhibitor omeprazole, the patient would still have “normal” serum levels (Tables 6 and 7).

| Activity Score CYP2D6 | Genetic Phenotype | Weak Inhibitor and Moderate Inhibitor | Strong Inhibitor |
|-----------------------|-------------------|--------------------------------------|-----------------|
| 0                     | PM                | Activity score × 0.5 = PM            | Activity score × 0 = PM |
| > 0 < 1.25            | IM                | Activity score × 0.5 = IM            | Activity score × 0 = PM |
| > 1.25 < 2.25         | NM                | Activity score × 0.5 = IM            | Activity score × 0 = PM |
| > 2.25                | UM                | Activity score × 0.5 = NM            | Activity score × 0 = PM |
Table 7. Phenoconversion in CYP2C19, and the calculation of the activity scores and the resulting phenotype.

| Genetic Phenotype CYP2C19 | Comedication of a Moderate or Strong Inhibitor; Predicted Phenotype |
|---------------------------|---------------------------------------------------------------|
| NM, IM                    | PM                                                            |
| RM, UM                    | IM                                                            |
| PM                        | PM                                                            |

Comedication of a moderate or strong inducer; Predicted phenotype

| NM, RM                    | UM                                                            |
| IM                        | NM                                                            |
| PM                        | PM                                                            |
| UM                        | UM                                                            |

Drug interactions (inhibition or induction) tend to be clinically relevant if the phenotype in the main metabolism pathway is of a poor or intermediate metabolizer status. Those patients are more sensitive to minor changes in usually less relevant pathways that occur if weak or moderate inhibitors are added to the drug therapy. For example, if a weak or moderate inhibitor of CYP3A4 is coadministered in a patient that receives a drug that is metabolized by CYP2D6 and CYP3A4 in combination and he has a CYP2D6-poor metabolizer status (main pathway). Such an interaction is more relevant than in a normal metabolizer patient, even though the same drugs are prescribed to both patients. There are a number of studies confirming that the relevance of the drug interaction depends on the genotype of the patient. Bahar showed in a PharmLine study how often, several pathways for the drug metabolism are affected by the drugs and genotypes [37]. In 55.1% of the patients, the study found a phenotype that required dose adaption; in 44.9%, he found a phenotype plus a drug interaction on a relevant pathway. He found that 9%, 47%, and 8.5% of participants were exposed to DDIs, DGIs, and DDGIs, respectively. Furthermore, there was an indication that the copresence of CYP3A4 IM/PM in individuals with CYP2C19 IM/PM exhibited an increased risk of switching and/or dose reduction of (es)citalopram to a larger extent than the combination of CYP2C19 IM/PM and CYP3A4 NM (aOR: 4.38, 95% CI: 1.22–15.69 and aOR: 2.75, 95% CI: 1.03–7.29, respectively). DDGIs also seemed to increase the risk of drug switching and/or dose reduction (aOR: 2.33, 95% CI: 0.42–12.78).

Additionally, Storelli showed that CYP2D6 NMs carrying a nonfunctional allele are at particular risk of phenoconversion to a poor metabolizer status in the presence of CYP2D6 inhibitors [38]. Seventeen homozygous carriers of two fully functional alleles and 17 heterozygous carriers of one fully functional and one nonfunctional allele participated in Storelli’s analysis. Dextromethorphan 5 mg and tramadol 10 mg were applied at each of the three study sessions. CYP2D6 was inhibited by duloxetine 60 mg (session 2) and paroxetine 20 mg (session 3). A higher rate of phenoconversion to intermediate metabolizers with duloxetine (71% vs. 25%, \( p = 0.009 \)) and to poor metabolizers with paroxetine (94% vs. 56%, \( p = 0.011 \)) was observed in heterozygous compared with homozygous normal metabolizers. The magnitude of the DDI between dextromethorphan and paroxetine was higher in homozygous than in heterozygous subjects (14.6 vs. 8.5, \( p < 0.028 \)). This strongly suggests that genetic normal metabolizers may not represent a homogenous population and that available genetic data should be considered when addressing DDIs in clinical practice. In consequence, the laboratories need to report genotypes and phenotypes.

Verbeurgt also analyzed the prevalence of DDIs, DGIs, and DDGIs and found 1053 potential major or substantial interactions in a cohort of 501 individuals. DDIs accounted for 66.1% of the total interactions. The remaining 33.9% of interactions were DGIs (14.7%) and DDGIs (19.2%). Interestingly, when compared with DDIs alone, DGIs and DDGIs increased
the total number of potentially clinically significant interactions by 51.3%, showing how important PGx testing in clinical practice is [39]. In psychopharmacotherapy, Hefner et al. found that, in a cohort of 27,396 psychiatric inpatients, 14.4% received a CYP inhibitor or inducer, opening the way for phenoconversion, as described in Tables 6 and 7 [40]. The most frequently prescribed CYP inhibitors were melperone (n = 2504, 28.1%) and duloxetine (n = 1324, 14.9%). Overall, 51.0% of the cases taking melperone were combined with a victim drug (n = 1288). Carbamazepine was the most frequently prescribed CYP inducer (n = 733, 88.8%), and within those cases, a combination with victim drugs were detected for 58% (n = 427). Finally, a relevant DDI was detected in 43.6% of the cases in which a CYP inhibitor or inducer was prescribed.

However, DDGIs may even be caused by a combination of substrates. Monte analyzed a cohort of patients receiving dextromethorpan, a CYP2D6 substrate. The coingestion of another CYP2D6-dependent drug was 9.49 (95% CI: 1.54, 186.41; p = 0.01) times more likely to have genotype–phenotype discordance based upon the 3-h DX/DM ratio. CYP2D6 substrate coingestions also caused genotype–phenotype discordance [41]. However, it is important to state that these findings need confirmation in other, larger (future) studies.

However, phenoconversion does not always result in a changed phenotype, e.g., if a poor metabolizer of CYP2C19 receives a CYP2C19 inducer, the phenotype remains PM, because more “loss of function proteins” will be synthesised, which does not increase the clearance of the drug. Moreover, if poor metabolizers receive a strong inhibitor for the same enzyme, there is no change in drug clearance either, since their phenotype does not change. Such an activity score–phenoconversion table does already exist for CYP2D6 and CYP2C19 (Tables 6 and 7).

Predicting the phenotype from genotype in clinical practice for individualizing therapy becomes virtually impossible when individuals start taking commonly prescribed, and widely used, CYP2C19 inhibitors such as the PPI omeprazole. Klieber at al. recommended using a pantoprazole-13C breath test (Ptz-BT) to define the phenotype when coadministered with CYP inhibitors omeprazole and esomeprazole [42]. After 28 days of PPI therapy, a genotype–phenotype discordance was discovered in 27 out of 29 non-PM patients (93%). Interestingly, all intermediate metabolizers were converted to poor metabolizers, but the normal metabolizers were either converted to intermediate or poor metabolizers. The use of commonly and widely prescribed CYP2C19 inhibitors—omeprazole and esomprazole—led to a phenoconversion of CYP2C19 enzyme activity. Klomp et al. showed in their review that the effect of phenoconversion differs between individuals and between drugs. In detail, normal metabolizers are sometimes converted to IM or PM, which is probably due to DDGIs [43]. Van de Wouden et al., therefore, recommended a PGx passport for patients who were tested and to make the information available to all prescribers at all times [44].

9. Conclusions

Genetic variations markedly increase or ameliorate the severity of potential drug interactions and need to be considered when prescribing patients with polypharmacology. Preemptive PGx testing plus a drug–drug–gene interaction check to take phenoconversion into account could avoid adverse drug events. This could also improve the clinical recommendations (which drug to choose) and dose individualization for patients. It allows an assessment of the relevance of a pharmacokinetic drug interaction and, therefore, can help to minimize alert fatigue. It must be emphasized that only testing for certain CYP enzymes is a highly misleading strategy, because potential DDGIs could be missed. It is important to screen for a panel of SNPs, as proposed by DPWG and Bousman et al., when trying to predict a serum level of a drug and its efficacy and tolerability. Influx and eflux transporter polymorphisms, as well as phase I and II DME polymorphisms, influence the efficacy and tolerability of a drug. This increasing complexity of pharmacotherapy by polypharmacy, DDIs, DGI, DDGIs, and DGGIs makes a clinical pharmacist with skills in pharmacokinetics and PGx essential in a healthcare team in the future, if not even in the present. TDM, PGx testing, and drug interaction checks need to be combined to make valid interpretations
of the pharmacokinetic profile. Clinical studies need to be aware of phenoconversion and take all factors into account when interpreting TDM results or PGx results. In the future, recognizing DGIs, DDGIs, and DGGIs may lead to a more comprehensive method of identifying individuals who are at risk for adverse drug reactions. This may lead to a better reputation and clear role of PGx testing in the future and allow a more profound interpretation of TDM results.

Author Contributions: The authors both made substantial contributions to the conception of the work and the interpretation of the data. Both authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Lazarou, J.; Pomeranz, B.H.; Corey, P.N. Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-Analysis of Prospective Studies. *Surg. Anesthesiol.* 1999, 43, 53–54. [CrossRef]

2. Gurwitz, J.H.; Field, T.S.; Avorn, J.; McCormick, D.; Jain, S.; Eckler, M.; Benser, M.; Edmondson, A.C.; Bates, D.W. Incidence and preventability of adverse drug events in nursing homes. *Am. J. Med.* 2000, 109, 87–94. [CrossRef]

3. Leone, R.; Magro, L.; Moretti, U.; Cutroneo, P.; Moschini, M.; Motola, D.; Tuccori, M.; Conforti, A. Identifying Adverse Drug Reactions Associated with Drug-Drug Interactions Data Mining of a Spontaneous Reporting Database in Italy. *Drug Saf.* 2010, 33, 667–675. [CrossRef] [PubMed]

4. Hahn, M.; Roll, S.C. Validierung von Interaktionsdatenbanken in der Psychopharmakotherapie. *Der Nervenarzt* 2017, 89, 319–326. [CrossRef] [PubMed]

5. Baumann, P.; Hahn, M.; Roll, S.C.; Stämpfli, D. Psychiatrische Patienten fragen ihren Arzt und Apotheker—wie kann die ambulante Versorgung optimiert werden? *Psychopharmakotherapie* 2020, 27, 270–277.

6. Ramsey, L.B.; Ong, H.H.; Schildcrout, J.S.; Shi, Y.; Tang, L.A.; Hicks, J.K.; El Rouby, N.; Cavallari, L.H.; Tuteja, S.; Aquilante, C.L.; et al. Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients. *JAMA Netw. Open* 2020, 3, e2029411. [CrossRef] [PubMed]

7. Turner, R.M.; De Koning, E.M.; Fontana, V.; Thompson, A.; Pirmohamed, M. Multimorbidity, polypharmacy, and drug-drug-gene interactions following a non-ST elevation acute coronary syndrome: Analysis of a multicentre observational study. *BMC Med.* 2020, 18, 367. [CrossRef] [PubMed]

8. Abdullah-Koolmees, H.; van Keulen, A.M.; Nijenhuis, M.; Deneer, V.H.M. Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPx Guidelines. *Front. Pharmacol.* 2021, 11. [CrossRef]

9. De Leon, J. The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part I: A summary of the current state for clinicians. *Res. Psychiatr. Salud. Ment.* 2015, 8, 97–115. [CrossRef]

10. Fritz, D.; Ceschi, A.; Curkovic, I.; Huber, M.; Egbring, M.; Kullak-Ublick, G.A.; Russmann, S. Comparative evaluation of three clinical decision support systems: Prospective screening for medication errors in 100 medical inpatients. *Eur. J. Clin. Pharmacol.* 2012, 68, 1209–1219. [CrossRef] [PubMed]

11. Haueis, P.; Greil, W.; Huber, M.; Grohmann, R.; Kullak-Ublick, G.A.; Russmann, S. Evaluation of Drug Interactions in a Large Sample of Psychiatric Inpatients: A Data Interface for Mass Analysis With Clinical Decision Support Software. *Clin. Pharmacol. Ther.* 2011, 90, 588–596. [CrossRef] [PubMed]

12. Hedna, K.; Andersson, M.L.; Gyllensten, H.; Hägg, S.; Böttiger, Y. Clinical relevance of alerts from a decision support system, PHARAO, for drug safety assessment in the older adults. *BMC Geriatr.* 2019, 19, 164. [CrossRef] [PubMed]

13. U.S. Food and Drug Administration. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Last Updated 3/10/2020. 2019. Available online: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers (accessed on 28 April 2021).

14. Hiemke, C.; Bergemann, N.; Clement, H.W.; Conca, A.; Deckert, J.; Domschke, K.; Eckermann, G.; Egberts, K.; Gerlach, M.; Greiner, C.; et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. *Pharmacopsychiatry* 2018, 51, 9–62. [CrossRef] [PubMed]

15. Polasek, T.M.; Lin, F.P.Y.; Miners, J.O.; Doogue, M.P. Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: A criteria-based assessment. *Br. J. Clin. Pharmacol.* 2011, 71, 727–736. [CrossRef]

16. Guttmacher, A.E.; Collins, F.S. Genomic Medicine—A Primer. *N. Engl. J. Med.* 2002, 347, 1512–1520. [CrossRef]
17. Caudle, K.E.; Sangkuhl, K.; Whirl-Carrillo, M.; Swen, J.J.; Haidar, C.E.; Klein, T.E.; Gammal, R.S.; Relling, M.V.; Scott, S.A.; Hertz, D.L.; et al. Standardizing CYP 2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. *Clin. Transl. Sci.* 2020, 13, 116–124. [CrossRef]

18. Chang, M.; Tybring, G.; Dahl, M.J. Impact of Cytochrome P450 2C19 Polymorphisms on Citalopram/Escitalopram Exposure: A Systematic Review and Meta-Analysis. *Clin. Pharmacokinet.* 2014, 53, 801–811. [CrossRef]

19. Hahn, M.; Müller, D.J.; Roll, S.C. Frequencies of Genetic Polymorphisms of Clinically Relevant Gene-Drug Pairs in a German Psychiatric Inpatient Population. *Pharmacopsychiatry 2021*, 54, 81–89. [CrossRef]

20. Hicks, J.K.; Sangkuhl, K.; Swen, J.J.; Ellingrod, V.L.; Müller, D.J.; Shimoda, K.; Bishop, J.R.; Kharasch, E.D.; Skaar, T.C.; Gaedigk, A.; et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. *Clin. Pharmacol. Ther.* 2017, 102, 37–44. [CrossRef]

21. Gronich, N.; Lavi, I.; Lejbkowicz, F.; Pinchev, M.; Zoabi, Y.; Auriel, E.; Saliba, W.; Rennert, G. Ischemic stroke and myocardial ischemia in clopidogrel users and the association with CYP2C19 loss-of-function homozygosity: A real-world study. *Pharmacogenom. J.* 2021, 1–7. [CrossRef]

22. He, W.; Grassmann, F.; Eriksson, M.; Eliasson, E.; Margolin, S.; Thorén, L.; Hall, P.; Czenne, K. CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer. *J. Clin. Oncol.* 2020, 38, 548–557. [CrossRef] [PubMed]

23. Aleo, M.D.; Luo, Y.; Swiss, R.; Bonin, P.D.; Potter, D.M.; Will, Y. Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. *Hepatology* 2014, 60, 1015–1022. [CrossRef] [PubMed]

24. Ray, A.S.; Cihlar, T.; Robinson, K.L.; Tong, L.; Vela, J.E.; Fuller, M.D.; Wieman, L.M.; Eisenberg, E.J.; Rhodes, G.R. Mechanism of Active Renal Tubular Efflux of Tenofovir. *Antimicrob. Agents Chemother.* 2006, 50, 3297–3304. [CrossRef] [PubMed]

25. Kwan, P.; Brodie, M.J. Potential Role of Drug Transporters in the Pathogenesis of Medically Intractable Epilepsy. *Epilepsia 2005*, 46, 224–235. [CrossRef] [PubMed]

26. Van Vliet, E.A.; Van Schaik, R.; Edelbroek, P.M.; Redeker, S.; Aronica, E.; Wadman, W.J.; Marchi, N.; Vezzani, A.; Gorter, J.A.; Van Den Ouweland, B.; et al. The Clinical Impact of ABCB1 Polymorphisms on the Treatment of Psychiatric Diseases. *World J. Pharmacol.* 2013, 2, 222–240. [CrossRef] [PubMed]

27. Saiz-Rodríguez, M.; Belmonte, C.; Román, M.; Ochoa, D.; Jiang-Zheng, C.; Koller, D.; Mejia, G.; Zubiaur, P.; Wojnicz, A.; Abad-Santos, F. Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants. *Basic Clin. Pharmacol. Toxicol.* 2018, 123, 474–485. [CrossRef] [PubMed]

28. Saiz-Rodríguez, M.; Belmondo, C.; Román, M.; Ochoa, D.; Jiang-Zheng, C.; Koller, D.; Mejia, G.; Zubiaur, P.; Wojnicz, A.; Abad-Santos, F. Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants. *Basic Clin. Pharmacol. Toxicol.* 2018, 123, 474–485. [CrossRef] [PubMed]

29. Krajcsi, P. Drug-transporter interaction testing in drug discovery and development. *World J. Pharmacol.* 2013, 2, 35. [CrossRef]

30. Rosenhagen, M.C. The Clinical Impact of ABCB1 Polymorphisms on the Treatment of Psychiatric Diseases. *Curr. Pharm. Des.* 2011, 17, 2843–2851. [CrossRef] [PubMed]

31. Relling, M.V.; Schwab, M.; Whirl-Carrillo, M.; Suarez-Kurtz, G.; Pui, C.; Stein, C.M.; Moyer, A.M.; Evans, W.E.; Klein, T.E.; Antillon-Klussmann, F.G.; et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. *Clin. Pharmacol. Ther.* 2019, 105, 1095–1105. [CrossRef]

32. DeGorter, M.K.; Tirona, R.G.; Schwarz, U.I.; Choi, Y.-H.; Dresser, G.K.; Suskin, N.; Myers, K.; Zou, G.; Iwuchukwu, O.; Wei, W.-Q.; et al. Clinical and Pharmacogenetic Predictors of Circulating Atorvastatin and Rosuvastatin Concentrations in Routine Clinical Care. *Circ. Cardiovasc. Genet.* 2013, 6, 400–408. [CrossRef] [PubMed]

33. Mostafa, S.; Kirkpatrick, C.M.J.; Byron, K.; Sheffield, L. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes. *J. Neural Transm.* 2016, 123, 1–7. [CrossRef] [PubMed]

34. Drevin, G.; Picard, N.; Jouset, N.; Briet, M.; Abbara, C. Pitfalls and challenges associated with phenocconversion in forensic toxicology. *Forensic Sci. Int. Genet.* 2021, 51, 102433. [CrossRef] [PubMed]

35. Hefner, G.; Shams, M.E.E.; Unterecker, S.; Falter, T.; Hiemke, C. Inflammation and psychotropic drugs: The relationship between C-reactive protein and antipsychotic drug levels. *Psychopharmacol. 2016*, 233, 1695–1709. [CrossRef] [PubMed]

36. Shah, R.R.; Smith, R.L. Addressing phenocconversion: The Achilles’ heel of personalized medicine. *Br. J. Clin. Pharmacol.* 2015, 79, 222–240. [CrossRef]

37. Bahar, M.A.; Lanting, P.; Bos, J.H.J.; Sijmons, R.H.; Hak, E.; Wilfert, B. Impact of Drug-Gene-Interaction, Drug-Drug-Interaction, and Drug-Drug-Gene-Interaction on (es)Citalopram Therapy: The PharmLines Initiative. *J. Pers. Med.* 2020, 10, 256. [CrossRef]

38. Storelli, F.; Mattey, A.; Lenglet, S.; Thomas, A.; Desmeules, J.; Daali, Y. Impact of CYP2D6 Functional Allelic Variations on Phenocconversion and Drug-Drug Interactions. *Clin. Pharmacol. Ther.* 2017, 104, 148–157. [CrossRef]

39. Verbeurgt, P.; Mamiya, T.; Oesterheld, J. How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping. *Pharmacogenomics 2014*, 15, 655–665. [CrossRef]

40. Hefner, G.; Wolff, J.; Hahn, M.; Hiemke, C.; Toto, S.; Roll, S.C.; Messer, T.; Klimke, A. Prevalence and sort of pharmacokinetic drug–drug interactions in hospitalized psychiatric patients. *J. Neural Transm.* 2020, 127, 1185–1198. [CrossRef]
41. Monte, A.A.; West, K.; McDaniel, K.T.; Flaten, H.K.; Saben, J.; Shelton, S.; Abdelmawla, F.; Bushman, L.R.; Williamson, K.; Abbott, D.; et al. CYP2D6 Genotype Phenotype Discordance Due to Drug-Drug Interaction. *Clin. Pharmacol. Ther.* **2018**, *104*, 933–939. [CrossRef] [PubMed]

42. Klieber, M.; Oberacher, H.; Hofstaetter, S.; Beer, B.; Neururer, M.; Amann, A.; Alber, H.; Modak, A. CYP2C19 Phenoconversion by Routinely Prescribed Proton Pump Inhibitors Omeprazole and Esomeprazole: Clinical Implications for Personalized Medicines. *J. Pharmacol. Exp. Ther.* **2015**, *354*, 426–430. [CrossRef] [PubMed]

43. Klomp, S.D.; Manson, M.L.; Guchelaar, H.-J.; Swen, J.J. Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review. *J. Clin. Med.* **2020**, *9*, 2890. [CrossRef] [PubMed]

44. Van Der Wouden, C.H.; Van Rhenen, M.H.; Jama, W.O.; Ingelman-Sundberg, M.; Lauschke, V.M.; Konta, L.; Schwab, M.; Swen, J.J.; Guchelaar, H. Development of the PG x-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing. *Clin. Pharmacol. Ther.* **2019**, *106*, 866–873. [CrossRef] [PubMed]